BAY 41-2272

Key Product Details

Product Description

BAY 41-2272 is an activator of soluble guanylyl cyclase (sGC); acts at a nitric oxide (NO)-independent regulatory site in the sGC α₁ subunit. Inhibits platelet aggregation (IC₅₀ = 36 nM) and phenylephrine-induced contractions of rabbit aorta (IC₅₀ = 0.30 μM). Also reduces vascular smooth muscle growth through cAMP- and cGMP-dependent PKA and PKG pathways.

Product Specifications for BAY 41-2272

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for BAY 41-2272

The following data is based on the product molecular weight 360.39.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.77 mL	13.87 mL	27.75 mL
5 mM	0.55 mL	2.77 mL	5.55 mL
10 mM	0.28 mL	1.39 mL	2.77 mL
50 mM	0.06 mL	0.28 mL	0.55 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 6 publications citing the usage of this product.

• Joshi The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways. J.Pharmacol.Exp.Ther. 2011 PMID: 21825001
• Mittendorf Discovery of Riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 2009 PMID: 19263460
• Stasch NO-independent regulatory site on soluble guanylate cyclase. Nature 2010 PMID: 11242081

Product Documents for BAY 41-2272